Biktarvy 50 mg/200 mg/25 mg film-coated tablets clinical trials
9 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease -The Late Presenter Treatment Optimisation Study (LAPTOP)-
This study compares different HIV treatments for people diagnosed with advanced HIV. It looks at how well new drug combinations work to control the virus and improve health, including using Biktarvy and Symtuza. The main goal is to find the most effective treatment.
For: Patients who present late on during their acquisition of the HIV-1 (Human Immunodeficiency Virus)Spain · Ireland · Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen in people living with HIV of at least 50 years of age who are virologically suppressed
This study is looking at an HIV medication called Dovato. It's for people aged 50 or older who are already stable on another HIV medicine, Biktarvy. Researchers want to see if switching to Dovato is safe, works well, and is easy to take.
For: Human immunodeficiency virus (HIV)Belgium · Italy · Portugal - Ongoing, recruitingTherapeutic use (Phase IV)
A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB + RPV
This study looks at a new one-pill treatment for HIV, called Biktarvy, after people stop a different injectable HIV medicine. Researchers want to see if Biktarvy is safe, how well the body uses it, and if it keeps HIV under control for adults.
For: HIV-1 infectionFrance - Ongoing, recruitingTherapeutic use (Phase IV)
Phase IV, Randomized, Multicenter, Double-Blind Clinical Trial Designed to Evaluate the Safety and Appropriateness of Switching from DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control, and Neuropsychiatric Vulnerabilities: MIND Study
This study is looking at how switching HIV medication might affect your mood, thinking, and sleep. It's for people with HIV who are doing well on their current treatment but might have some brain-related symptoms. Researchers want to see if switching to Biktarvy is safe and helpful.
For: HIVSpain - Ongoing, recruitingPhase III and phase IV (Integrated)
DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV: an open-label randomized clinical trial
This study compares two common HIV treatments, Biktarvy and Dovato, to see if they are equally good at keeping the virus under control. Researchers want to find out if Dovato is as effective as Biktarvy in maintaining a very low amount of HIV in the blood.
For: HIVSpain - Ongoing, recruitingTherapeutic use (Phase IV)
Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial.
This study looks at how well two different HIV treatments, Biktarvy and Dovato, work in people living with HIV. It compares a 2-drug treatment to a 3-drug treatment to see which is more effective at controlling the virus and keeping the immune system healthy.
For: human immunodeficiency viruses (HIV)Belgium - Ongoing, recruitingTherapeutic use (Phase IV)
Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)
This study looks at how HIV medicines work in pregnant women. Researchers want to understand how the medicines are absorbed, used, and leave the body during and after pregnancy, and how they might affect babies. It's for women living with HIV who are pregnant or have recently given birth.
For: HIV-infectedSpain · Ireland · Netherlands - Ongoing, recruitingPhase II and Phase III (Integrated)
An Operationally Seamless Phase 2/3, Randomized, Active Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination with GS-4182 Versus Biktarvy in Treatment Naive People with HIV-1
This study is testing new medicines for people recently diagnosed with HIV-1. It compares a weekly pill combining GS-1720 and GS-4182 against a daily pill called Biktarvy. The main goal is to see which treatment best controls the virus.
For: HIV-1 InfectionRomania · Spain · Poland - AuthorisedPhase II and Phase III (Integrated)
An Operationally Seamless Phase 2/3, Randomized, Active -Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1
This study is testing a new weekly pill for HIV to see if it's as good as a daily pill people already take. It's for adults whose HIV is already under control. We want to check how safe and effective the new weekly treatment is.
For: HIV-1 InfectionFrance · Germany · Poland